Open Access

Incidence of unlicensed and off-label prescription in children

Italian Journal of Pediatrics201440:12

DOI: 10.1186/1824-7288-40-12

Received: 29 August 2013

Accepted: 15 January 2014

Published: 4 February 2014

Abstract

Background

Many common drugs have not been licensed for use in children.

Methods

This study evaluated the incidence of unlicensed and off-label prescriptions at the Department of Pediatrics during a period of six months. A total of 8,559 prescriptions for 4,282 children were processed.

Results

Off-label and unlicensed prescriptions were found in 9.01% and 1.26% of all prescriptions, respectively. Unlicensed prescriptions were significantly more common in boys (1.5%) than in girls (1.0%) (p = 0.037). There was no significant difference between off-label prescriptions in boys (9.0%) and in girls (9.1%) (p = 0.89). The prescription of unlicensed drugs was significantly more frequent in school age children (p < 0.0001). The most commonly prescribed unlicensed drugs were angiotensin-converting enzyme inhibitors; among off-label drugs, antihistamines and bronchodilators.

Conclusions

This study shows that the incidence of unlicensed and off-label drug prescriptions in our patients is not as high as in other studies.

Keywords

Prescribing habits Off-label drug use Pediatric outpatient clinics

Introduction

Many common drugs used to treat children are either not licensed for use in children at all (unlicensed drugs) or are prescribed outside the terms of the product licence (off-label prescription)[1]. Drugs can be prescribed off-label for younger children, in a different dose, for a different indication or by a different route of administration than which the drug is licensed for. The use of unlicensed and off-label medicines in children is common because clinical trials have not usually been performed in children during the research and development process. Consequently, the information available to pediatricians may not always be as detailed or as robust as when prescribing a medicine that is licensed for an approved indication. This has led to concerns that children can receive drugs at dosages that either lack efficacy or exhibit safety problems. The latter in particular has received a great deal of attention[2, 3].

Childhood diseases may be different from their adult equivalents. This may affect either the benefit and/or the risk of therapy. The lack of reliable data in the pediatric population is associated with specific problems, including limited availability of safety data due to the lack of clinical trials and insufficient pharmacokinetic data or dose-finding studies. Maturation, growth and development make the pediatric population susceptible to drug-induced growth and development disorders as well as to delayed adverse drug reactions (ADRs). Pediatricians should be aware that the use of drugs prescribed off-label may increase the risk of adverse reactions[4].

Based on this, there was a need for a legal obligation for pharmaceutical companies to perform studies if they intended to develop medicines for use in the pediatric population. In 1997, the European Commission discussed problematic issues of pediatric medicines. One of the conclusions was that there was a need to strengthen the legislation. In 1998, the Commission supported the need for international discussion on the performance of clinical trials in children in the context of the International Conference on Harmonization (ICH) – an organization working on the harmonization of pharmaceutical regulatory requirements between the EU, Japan and the US. An ICH guideline was therefore adopted. The goals were to encourage and facilitate timely pediatric medicinal product development internationally, and to provide an outline of critical issues in pediatric drug development and approaches to a safe, efficient and ethical study of medicinal products. Subsequently, the ICH guideline became the European guideline. The Directive on Good Clinical Practice for Clinical Trials came fully into force in 2004. This Directive takes into account some specific concerns about performing clinical trials in children, and it lays down criteria for their protection in clinical trials[5].

Moreover, off-label use of medicines in children is still common. As reported by Santos et al., off-label drug use affects 36%–92% of hospitalized children[6]. Therefore, we intended to evaluate the current incidence of unlicensed and off-label prescriptions in outpatients during a period of six months to identify the drugs requiring an extension of registration for younger children.

Methods

Study design and setting, study population

Prescription data of all outpatients aged 0–15 years attending the University Hospital Olomouc, Czech Republic, during a 6-month period (from 1st January to 30th June 2012) were processed. Patients who reached 15 years of age in the follow-up period were included in the study population. Patients older than 15 years did not enter this study. The following characteristics were recorded for each patient: age, sex, and the number of prescriptions. In addition, the incidence of unlicensed and off-label prescription of drugs was recorded and the drugs most commonly prescribed were identified.

Consent

The study was conducted following the guidelines of the Declaration of Helsinki. Written informed consent to participate was not required because this was an observational study. During the study no medical interventions were done.

Ethical approval

All ethical considerations were followed. Patient files were processed anonymously. No personal data were collected. The research project was approved by FN and LF UP Olomouc Institutional Ethical/Review Board.

Data processing

Terms of the license were obtained from the Summary of Product Characteristics. The drugs that were not explicitly licensed for use in children were considered as unlicensed. The off-label category included all medicines where the prescription showed a discrepancy with the licence information for age; i.e. if the drug was prescribed for a younger child than for which age it was licensed.

Statistical analysis

For all the data analyses, Pearson’s chi-square test was used. It tested a null hypothesis stating that the frequency distribution of certain events observed in a sample was consistent with a particular theoretical distribution. The events considered had to be mutually exclusive and had to have total probability. Confidence intervals were stated at the 95% level.

Results

A total of 4,282 outpatients younger than 15 years of age entered the study. During the 6-month follow-up period, they received 8,559 prescriptions. The descriptive statistics of the study cohort are given in Table 1. Unlicensed drugs were prescribed in 1.26% (95% CI 1.02–1.50); off-label drugs were prescribed in 9.01% (95% CI 8.40–9.62) of all prescriptions. The distribution of unlicensed and off-label drug use in different age categories is shown in Table 2.
Table 1

Distribution of the number of patients and prescriptions in different age categories

Age category

Age

Patients

Females

Prescriptions in females

Males

Prescriptions in males

Prescriptions total

Total prescriptions per patient

Newborns

0–1 m

18

5

5

13

17

22

1.22

Infants

1 m–1 yr

304

133

214

168

283

497

1.63

Toddlers

1–3 yrs

609

308

515

301

514

1029

1.69

Preschoolers

3–6 yrs

1027

626

1249

401

774

2023

1.97

Early school age children

6–11 yrs

1296

763

1516

533

1164

2680

2.07

School age children

11–15 yrs

1028

465

1076

563

1232

2308

2.25

Total

0–15 yrs

4282

2300

4575

1979

3984

8559

2.00

Table 2

Distribution of unlicensed and off-label prescriptions in different age categorie s

 

Prescriptions total

Unlicensed

Off-label

Newborns

22

0

9

Infants

497

1

71

Toddlers

1029

0

134

Preschoolers

2023

16

309

Early school age children

2680

29

156

School age children

2308

62

93

Total

8559

108

772

Drugs prescribed unlicensed were significantly more common in boys (1.5%, 95% CI 1.15–1.91) than in girls (1.0%, 95% CI 0.74–1.32) (p = 0.037). There was no significant difference between off-label prescription in boys (9.0%, 95% CI 8.08–9.85) and in girls (9.1%, 95% CI 8.22–9.88) (p = 0.89). See Table 3.
Table 3

Gender-related distribution of unlicensed and off-label prescriptions

 

Total

Unlicensed

Off-label

Males

3984

61

358

Females

4575

47

414

Total

8559

108

772

Unlicensed use of drugs was significantly more frequent in school age children than in any other age categories (p < 0.0001). Unlicensed drugs were prescribed in 2.7% (95% CI 2.07–3.40) of school age children (11–15 years), in 1.0% (95% CI 0.69–1.47) of early school age children (7–11 years) and in less than 1.0% in other age categories. There has been a significant difference in the frequency of off-label drug use between individual age categories (p < 0.0001). Drugs were most frequently prescribed off-label for newborns (40.9%, 95% CI 20.36–61.45), but could not be evaluated because of a low number of patients of this age in our study. Drugs prescribed off-label were more frequently found in infants (14.3%, 95% CI 11.21–17.36), toddlers (13.0%, 95% CI 10.97–15.08) and preschool age children (15.3%, 95% CI 13.72–16.86).

The individual drugs most commonly prescribed unlicensed and off-label are presented in Tables 4 and5. The most commonly prescribed unlicensed drugs were angiotensin-converting enzyme (ACE) inhibitors (ramipril and enalapril). The prescription of ramipril occurred in 24 prescriptions. Of this total, 17 prescriptions were for boys (in 12 individuals) and 7 for girls (4 individuals). Among off-label drugs, antihistamines (desloratadine and cetirizine) and bronchodilators were the most common.
Table 4

Drugs most commonly prescribed unlicensed

Generic name

Trade name

Prescriptions

Patients

Porcine transfer factor

Imunor por. lyo. 4 × 10 mg

6

5

Cyproterone

Androcur-50 tbl. 50 × 50 mg

5

5

Ramipril

Tritace tbl. 50 × 1,25 mg

5

5

Enalapril

Apo-enalapril tbl. 100 × 5 mg

4

4

Ramipril

Tritace tbl. 50 × 5 mg

3

3

Ramipril

Tritace tbl. 30 × 2,5 mg

3

3

Ramipril

Amprilan tbl. 30 × 2,5 mg

3

2

Metoclopramide

Degan tbl. 40 × 10 mg

3

3

Atenolol

Tenormin tbl. 28 × 50 mg

3

2

Ramipril

Tritace tbl. 50 × 2,5 mg

2

2

(Drugs licensed for adults only).

por. lyo. – oral lyophilisate.

tbl. – tablet.

Table 5

Drugs most commonly prescribed off-label

Generic name

Trade name

Prescriptions

Patients

Approved for patients older than (years)

Salbutamol

Ventolin inhaler N 200 × 100RG

43

42

4

Desloratadine

Aerius tbl.dis. 90 × 2,5 mg

48

47

6

Mometasone

Nasonex nasal spray 140 × 50RG

32

30

6

Desloratadine

Aerius tbl. 90 × 5 mg

34

33

12

Cetirizine

Zodac gtt. 1 × 20 ml

28

28

2

Clarithromycin

Klacid tbl. 14 × 250 mg

28

26

12

Fluticasone furoate

Avamys nasal spray 120 × 27,5RG

25

22

6

Codeine

Codein Slovakofarma tbl. 10 × 15 mg

14

13

12

Promethazine

Prothazin tbl. 20 × 25 mg

14

14

10

Montelukast

Singulair 5 Junior tbl.mnd. 98 × 5 mg

14

14

6

Phenoxymethylpenicillin

Ospen 500 tbl. 30 × 500KU

17

17

6

Desloratadine

Aerius tbl. 50 × 5 mg

14

14

12

tbl. – tablet.

tbl. dis. – orodispersible tablet.

tbl. mnd. – chewable tablet.

Discussion

Previous studies have shown that unlicensed and off-label drug use in children is common. As reported by Pandolfini and Bonati, off-label prescriptions in pediatric studies in the community affected 9%–33% of children[7].

Pandolfini and Bonati performed a literature review of all published studies on off-label and unlicensed drug use in children. A total of 30 studies from 1985 to 2004 were included. Eleven involved pediatric hospital wards, seven neonatal hospital wards, and twelve the community setting. The off-label and unlicensed classification methods varied, making the results difficult to compare. In general, off-label/unlicensed prescription rates ranged from 11% to 80%, and higher rates were found in younger versus older patients and in the hospital versus community settings. In the pediatric hospital wards, off-label/unlicensed prescriptions ranged from 16% to 62% and most often involved acetaminophen, cisapride, chloral hydrate and salbutamol. In the community setting, rates ranged from 11% to 37% and the most commonly prescribed unlicensed or off-label drugs were salbutamol and amoxicillin[7].

More recently, an interesting review of this area of interest was also published by Lindell-Osuagwu et al.[8]. However, the definition of unlicensed and off-label drug use varied among different studies. Therefore, the results are not directly comparable but provide an overall picture of the issue[8].

Unlike these earlier studies, our results show that the current incidence of unlicensed and off-label prescriptions in our outpatients is not as high as has been previously found. Drugs prescribed off-label were found in 9.01%; unlicensed drugs were identified in only 1.26% of all prescriptions.

The most frequently used drugs were searched for in a relatively recent study by Hsian et al.[9]. They conducted a prospective observational study at a pediatric ward in Germany between January and June 2006. The study included 417 patients for whom 1,812 prescriptions representing 211 different drugs were made. Unfortunately, in this study the term “off-label” was used for both unlicensed and off-label prescriptions. In total, 253 patients (61%) received at least one off-label prescription; 553 (31%) of all prescriptions were off-label. The five drug groups most frequently prescribed off-label were: cardiovascular drugs (60% of prescriptions), anti-infectives (42%), drugs of the respiratory system (30%), drugs of the alimentary tract and metabolism (25%) and analgesics and antipyretics (3%). The cardiovascular drugs also exhibited the highest number of drugs prescribed off-label due to the patient’s age[9].

In our study, the cardiovascular drugs (mainly ACE inhibitors and beta blockers) were also among the most frequently prescribed unlicensed drugs. Their use is sometimes necessary, because no effective licensed alternatives are available. This is mainly the case of captopril or enalapril used in children with hypertension or heart failure. This finding highlights the necessity of registering cardiovascular drugs for younger children as well.

Recent studies also show a relationship between off-label and unlicensed drug prescribing and age. This prescription was repeatedly found to be most common in newborns. The younger the child, the more likely he/she is to get an off-label or unlicensed drug prescription. This was found mainly in the hospital care. On the contrary, in outpatient settings, a higher rate of these prescriptions has been found in adolescents. There is only a slight difference between individual countries where studies were performed[8, 9].

The results of our study were influenced by number of patients in each age category. The prescription of unlicensed drugs was significantly more frequent in school age children than in any other age group. In this category, there is also the highest number of prescriptions per patient. It is probably caused by the morbidity of children. The older the child, the higher is the risk of multiple therapies due to chronic diseases. Off-label prescriptions were most frequent in newborns, but the low number of patients in this age category prevented making any definite conclusions.

Drugs prescribed unlicensed were significantly more common in boys than in girls, but there was no such gender-related difference in off-label prescription. This difference was found to be caused by several unlicensed cardiovascular drugs, which were prescribed in boys more often.

It is surprising that only very few recent studies have evaluated the link between gender and unlicensed or off-label drug prescribing. One of them is a study by Santos et al. No statistically significant differences between boys and girls were found, however with some exceptions: the prevalence of corticosteroids for systemic use was higher in females than males (among children under 1 year only), and the same was observed for anti-asthmatics among 2–5-year-old children and for diuretics in children under 6 years of age[6].

In our study, more boys were treated with ACE inhibitors. The main reason is that ramipril is not licensed for children and it was substantially more commonly prescribed in boys (M/F ratio 12:4). This might be influenced by a higher incidence of cardiovascular diseases in boys. The most common indication for ramipril was hypertension, particularly caused by renal impairment. In the majority of cases, the hypertension in boys was caused by polycystic kidney disease (PKD), an autosomal recessive disease, a significant cause of renal and liver-related morbidity in children and adolescents[10]. However, no relationship between sex and PKD has been described[11].

More probable explanations are offered in a recent study that discovered that boys had significantly higher values for height, body weight, waist circumference, BMI and systolic blood pressure than girls. Diastolic blood pressure tends to be higher in boys than in girls[12]. This can explain the intersexual difference in ACE inhibitors use found in our study, but further research into this topic is needed.

The majority of drugs prescribed off-label were antihistamines and drugs used to treat respiratory diseases. These drugs are usually licensed for children older than 6 years. The incidence of allergic and respiratory diseases in preschool children is very high[13], therefore antihistamines belong to the most frequently prescribed drugs for them. The first generation of antihistamines has never been clinically tested in children; nevertheless, it is widely used[14]. Therefore, clinical trials in younger children and extension of registration also for younger patients are needed.

Salbutamol in the form of pressurized suspension for inhalation was the individual active agent most frequently prescribed off-label. This result is consistent with those of several other studies[1518]. Salbutamol has only been approved for children older than 4 years, i.e. its prescription for younger patients is off-label. For younger children, only liquid drug formulation (salbutamol syrup) is available. However, the use of inhalation drug form is often more suitable. Thus, an extension of its licence would also be advisable.

Conclusions

Unlicensed and off-label prescribing in children is common and widespread. The problem has been recognized by many researchers[1821]. Our goal was to determine the extent of use of drugs that are not specifically licensed for use in children (unlicensed) and of those used outside the terms of their licence (off-label) with respect to the age of the child. This study shows that the incidence of unlicensed and off-label drug prescriptions in our patients is not as high as in other studies. Drugs prescribed off-label and unlicensed were found in 9.01% and 1.26% of all prescriptions, respectively. Although the quality of drug therapy is not necessarily related to drug license status, pediatricians should avoid exposing children to unnecessary risks and depriving them of potentially effective pharmacotherapy. To achieve this goal, an amendment of legislation to facilitate and encourage pediatric clinical trials is in process. The results of our study could guide the researchers to perform future trials mainly on cardiovascular drugs, antihistamines and respiratory system drugs.

Declarations

Acknowledgements

The study was supported by internal university grant IGA UPOL LF_2013_007.

Authors’ Affiliations

(1)
Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc

References

  1. Turner S, Longworth A, Nunn AJ, Choonara I: Unlicensed and off label drug use in paediatric wards: prospective study. BMJ. 1998, 316 (7128): 343-345. 10.1136/bmj.316.7128.343.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Mason J, Pirmohamed M, Nunn T: Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol. 2012, 68 (1): 21-28. 10.1007/s00228-011-1097-1.View ArticlePubMedGoogle Scholar
  3. Strnadová V: O čem se diskutuje v oblasti klinických studií. Klin Farmakol Farm. 2007, 21 (3–4): 119-121.Google Scholar
  4. Napoleone E: Children and ADRs (Adverse Drug Reactions). Ital J Pediatr. 2010, 36: 4-10.1186/1824-7288-36-4.PubMed CentralView ArticlePubMedGoogle Scholar
  5. European Medicines Agency: The European paediatric initiative: History of the Paediatric Regulation. 2007, London: EMEA, Doc. Ref: EMEA/17967/04 Rev 1Google Scholar
  6. Santos DB, Clavenna A, Bonati M, Coelho HL: Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008, 64 (11): 1111-1118. 10.1007/s00228-008-0543-1.View ArticlePubMedGoogle Scholar
  7. Pandolfini C, Bonati M: A literature review on off-label drug use in children. Eur J Pediatr. 2005, 164 (9): 552-558. 10.1007/s00431-005-1698-8.View ArticlePubMedGoogle Scholar
  8. Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H: Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther. 2009, 34 (3): 277-287. 10.1111/j.1365-2710.2008.01005.x.View ArticlePubMedGoogle Scholar
  9. Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt KG, Läer S: Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci. 2008, 30 (5): 497-502. 10.1007/s11096-008-9193-8.View ArticlePubMedGoogle Scholar
  10. Zhou XH, Hui ZY, Li Y: Clinical and pathological features of a neonate with autosomal recessive polycystic kidney disease caused by a nonsense PKHD1 mutation. World J Pediatr. 2013, 9 (1): 76-79. 10.1007/s12519-013-0407-3.View ArticlePubMedGoogle Scholar
  11. Grantham JJ, Nair V, Winklhoffer F: Cystic diseases of the kidney. Brenner & Rector’s The Kidney. Vol. 2. Edited by: Brenner BM. 2000, Philadelphia: WB Saunders Company, 1699-1730. 6Google Scholar
  12. Yang SJ, Kim S, Park H, Kim SM, Choi KM, Lim Y: Sex-dependent association between angiotensin-converting enzyme insertion/deletion polymorphism and obesity in relation to sodium intake in children. Nutrition. 2013, 29 (3): 525-530. 10.1016/j.nut.2012.09.001.View ArticlePubMedGoogle Scholar
  13. Rancière F, Nikasinovic L, Momas I: Dry night cough as a marker of allergy in preschool children: the PARIS birth cohort. Pediatr Allergy Immunol. 2013, 24 (2): 131-137. 10.1111/pai.12045.View ArticlePubMedGoogle Scholar
  14. Del Cuvillo A, Sastre J, Montoro J, Jáuregui I, Ferrer M, Dávila I: Use of antihistamines in pediatrics. J Investig Allergol Clin Immunol. 2007, 17 (Suppl 2): 28-40.PubMedGoogle Scholar
  15. Khdour MR, Hallak HO, Alayasa KS, AlShahed QN, Hawwa AF, McElnay JC: Extent and nature of unlicensed and off-label medicine use in hospitalised children in Palestine. Int J Clin Pharm. 2011, 33 (4): 650-655. 10.1007/s11096-011-9520-3.View ArticlePubMedGoogle Scholar
  16. Ballard CD, Peterson GM, Thompson AJ, Beggs SA: Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health. 2013, 49 (1): 38-42. 10.1111/jpc.12065.View ArticlePubMedGoogle Scholar
  17. Ribeiro M, Jorge A, Macedo AF: Off-label drug prescribing in a Portuguese Paediatric Emergency Unit. Int J Clin Pharm. 2013, 35 (1): 30-36. 10.1007/s11096-012-9699-y.View ArticlePubMedGoogle Scholar
  18. Ekins-Daukes S, Helms PJ, Taylor MW, McLay JS: Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol. 2005, 60 (2): 145-149. 10.1111/j.1365-2125.2005.02397.x.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H: Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000, 320 (7227): 79-82. 10.1136/bmj.320.7227.79.PubMed CentralView ArticlePubMedGoogle Scholar
  20. ‘t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D: A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001, 108 (5): 1089-1093. 10.1542/peds.108.5.1089.View ArticlePubMedGoogle Scholar
  21. Schirm E, Tobi H, de Jong-van den Berg LT: Unlicensed and off label drug use by children in the community: cross sectional study. BMJ. 2002, 324 (7349): 1312-1313. 10.1136/bmj.324.7349.1312.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Langerová et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Advertisement